Editas Medicine (EDIT) Prices Public Offering to Raise Up to $319.4 Million

Editas Medicine (NASDAQ: EDIT) priced a public offering of its common stock on May 26, 2026, targeting gross proceeds of up to $319.4 million. The gene editing company did not disclose the specific number of shares offered or the per-share price in its initial filing, but the transaction includes a customary underwriters’ option to purchase additional shares. The offering is expected to close on or around May 29, 2026, subject to standard closing conditions. Editas intends to use the net proceeds to advance its pipeline of CRISPR-based therapies, including treatments for sickle cell disease and ocular disorders, as well as for working capital and general corporate purposes. The offering is managed by a syndicate of investment banks, with Jefferies and Morgan Stanley serving as joint book-running managers. The capital raise comes at a pivotal time for the biotech sector, where clinical-stage companies continue to seek funding to support expensive late-stage trials and potential commercialization efforts. Editas had not yet disclosed updated cash reserves or quarterly earnings at the time of the announcement.